Skip to content
Search

Latest Stories

Pharmacist-led study warns against substandard hand sanitisers

Consumers face a ‘real risk’ of purchasing hand cleaners with low or inadequate concentrations of alcohol, a new study has warned.

The researchers, who looked at the effectiveness of hand sanitisers in the fight against COVID-19, added that such products “cannot ensure disinfection and are not fit for use”.


“Much more worrying is the presence of hand cleaners on the market containing low (“substandard”) and/or unknown concentrations of alcohol that are not commercialised as disinfectants,” the study, published in the International Journal of Pharmaceutics, states.

“There is a tangible risk that consumers might, and are using, hand cleaners, which product appearance is very similar to hand disinfectants, while being unaware that such products cannot ensure disinfection and are not fit for use amid the CoViD-19 pandemic.”

The study suggests pharmacists and retailers to advise customers over the selection of appropriate products to minimise the risk. The authors also call for awareness campaigns among the public and a review of current rules on hand sanitisers by the regulators.

The research, a collaboration between eight pharmacists based at universities in the UK, Italy and Jordan, analysed hand sanitisers available on the Italian market. It also proposes detailed “recipes” for the manufacture of effective hand sanitising gels.

The researchers also believe that the current demand for the hand sanitisers is likely to remain high for long.

“Public awareness on the importance of hand sanitisation during this pandemic is likely to have long term effects on hygiene habits across the world. The public is likely to endure the routine use of hand sanitisers, even beyond the CoViD-19 era, as a new norm of self-hygiene,” the article reads.

The University of Huddersfield has been the participating institution from the UK in the study.

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less